How do SSRIs work for perimenopause?

SSRIs, or selective serotonin reuptake inhibitors, are a class of medications that increase the availability of serotonin in the synapses between neurons by blocking the serotonin transporter protein (SERT), which would normally reabsorb serotonin into the presynaptic neuron after it has been released. By keeping serotonin active in the synapse longer, SSRIs enhance serotonergic neurotransmission throughout the brain and, through these effects, address both the thermoregulatory instability that drives hot flashes and the mood disturbances that often accompany perimenopause.

For hot flashes, the mechanism relates to serotonin's role in hypothalamic thermoregulation. The hypothalamus regulates core body temperature through circuits that receive serotonergic input. Estrogen normally modulates these circuits to maintain a stable temperature zone. When estrogen declines, the thermoregulatory threshold becomes dysregulated. SSRIs appear to recalibrate this system by restoring serotonergic tone in the hypothalamic circuits that control vasomotor responses, raising the threshold at which the cooling cascade (hot flash) is triggered. This is not a hormonal intervention but a neurotransmitter-level approach that addresses the same downstream destabilization that estrogen decline causes.

Paroxetine at 7.5 mg per day (brand name Brisdelle) is the only FDA-approved non-hormonal treatment specifically for moderate to severe vasomotor symptoms (hot flashes and night sweats). It uses a lower dose of paroxetine than is used for treating depression, which is typically 20 to 50 mg. The lower dose achieves thermoregulatory benefit with somewhat fewer side effects than full antidepressant doses, though side effects are still possible.

Other SSRIs used off-label for perimenopausal hot flash management include escitalopram, citalopram, and fluoxetine. Escitalopram has among the best evidence in this class, demonstrated in the MsFLASH trial published in JAMA in 2011: escitalopram at 10 to 20 mg daily reduced hot flash frequency by 47 percent and severity by 54 percent compared to placebo in perimenopausal and postmenopausal women. Citalopram has shown similar benefits in smaller trials. Fluoxetine's evidence is somewhat weaker for hot flash specifically, though it still outperforms placebo.

For perimenopausal women experiencing both hot flashes and mood symptoms, anxiety, or depression, SSRIs offer particular value because the same medication addresses multiple symptom domains simultaneously. Estrogen supports serotonin synthesis and receptor sensitivity, so estrogen's decline during perimenopause directly disrupts serotonergic mood regulation. Restoring serotonergic tone with an SSRI addresses this biological root of perimenopausal mood dysregulation, not just the surface emotional experience. Women who are experiencing clinical depression during perimenopause may need the full antidepressant dose range rather than the lower hot flash-focused doses.

An important clinical interaction must be clearly addressed: paroxetine is a potent inhibitor of the CYP2D6 hepatic enzyme. Women taking tamoxifen for breast cancer prevention or treatment absolutely should not use paroxetine. Tamoxifen requires CYP2D6-mediated conversion to its active metabolite, endoxifen, to exert its anti-cancer effects. Paroxetine co-administration substantially reduces endoxifen levels, potentially undermining tamoxifen's effectiveness. Among the other SSRIs, citalopram and escitalopram have minimal CYP2D6 inhibition and are preferred for women on tamoxifen, though the oncology team should always be consulted before adding any medication.

Common side effects of SSRIs for perimenopausal use include nausea in the first one to two weeks (often resolves spontaneously), headache, sleep changes, sexual dysfunction (reduced libido or difficulty with orgasm, which can be particularly unwelcome during a stage of life where libido may already be reduced), dry mouth, and initial anxiety. At the lower doses used for hot flash management, side effects tend to be milder than at full antidepressant doses.

Discontinuation should always be gradual, particularly with paroxetine, which has the most pronounced discontinuation syndrome of the commonly used SSRIs. Stopping paroxetine abruptly can cause dizziness, sensory disturbances sometimes described as electric shock sensations in the head, nausea, and mood changes.

Tracking your symptoms over time, using a tool like PeriPlan, can help you compare hot flash frequency and mood before and after starting an SSRI, and track any side effects worth discussing with your provider.

When to talk to your doctor: SSRIs require a prescription. Discuss any tamoxifen use, existing psychiatric medications, history of bipolar disorder, and whether you are also seeking help with mood, since the ideal SSRI choice and dose may differ depending on whether hot flash management alone or broader mood treatment is the goal.

This content is for informational purposes only and does not replace medical advice. Always consult your healthcare provider about your specific situation.